HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
about
Genetic draft and quasi-neutrality in large facultatively sexual populationsExploiting Genetic Interference for Antiviral TherapyThe site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytesPathogenesis of human immunodeficiency virus infectionMultidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapyABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansFifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroL-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitroIdentification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitorsAnti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusionGreatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidineComparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinationsBiological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugsIn vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitorsComparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virusAn antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivativesPotent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptaseDetection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridizationBI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudineOxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproductionPyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activityViral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitorsHP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses HZidovudine-resistant human immunodeficiency virus selected by passage in cell cultureNonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replicationHuman immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue cultureIsolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptaseIn vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosineAntiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseSynergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitroMutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidineDidanosine therapy in patients intolerant of or failing zidovudine therapyAnti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivativesAn inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infectionAnti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analogSynergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro
P2860
Q22065128-5F4EDB75-5B12-4EED-A5CF-ABDC692F2B48Q24288775-DE8C7E7A-4942-4FF6-8005-47DC9C0D4673Q24564579-EE6EF58C-D794-4313-9846-1EBE169FEEFEQ24634681-3C1A505D-5907-48C6-9A78-BA6C7D39E653Q24684152-1DD77830-C374-4A44-B0BA-6F227CD6CE33Q27729982-9C4244A0-7B5C-4465-8B9B-58A3DE4359D9Q28316118-4006154F-0312-4C5D-9B5D-ABDECDEACF5CQ28316183-3720ED82-416C-4406-A8ED-F3B1361C4ABAQ28316326-C73D717B-5F86-4BBF-AFF6-30DFFED28C9BQ28316334-2C0B6F7A-1F48-4546-8057-4F21F88C1BDCQ28316336-50A75C60-B488-4AF9-B79F-682A9B034986Q28316430-FAAE32BB-B6BF-46C5-AB4C-6731E8ECBA96Q28316971-63040187-C3E3-4048-B42D-E063646D85EAQ28318354-E2BE94F0-C65E-4B63-96FE-FEDE20E850ADQ28318473-3C7C1C58-5068-4DE4-81B3-04B84E01D161Q28318476-9D0BC2D9-C100-4D02-95DB-A81C4068CEF9Q28321397-C05BA21B-8E70-49B8-B067-EE060C8DBF93Q28323307-F6589945-D0FE-406E-8E7B-88804B9C39E9Q28323353-A798873A-BE5D-4A4B-AC6C-69E5A69D4318Q28323682-D243F8FE-8C3E-4921-8D35-10C52528E44BQ28323740-1C3481D3-BCF8-43B5-B364-95FF32706496Q28323773-B46F3F08-71FA-480E-9168-1ADDFF1C2DCCQ28323825-83085A6B-868F-4157-B860-A95811FFD052Q28323972-1745C702-D0CA-4ED5-8A7C-D3E81D447367Q28323976-46AEA4C5-16F1-4227-9975-72E6EF97580DQ28323994-3313646F-BE3C-4094-AC83-8CBDE50B8698Q28324003-BE2C7524-C333-4B17-9037-B268EF871C2FQ28324074-6DD2B0D6-767B-4046-B6B4-FE948D66F026Q28324100-97E3E317-8D11-40DE-A79D-C870715A4A79Q28324214-28434819-09E0-4478-BF86-956166410B67Q28324219-B2D8E490-0DEC-4BB3-A55C-CDD257A358DFQ28324338-0A5CE5F2-BA16-445D-B0FF-4113331A6253Q28325705-483734E1-AA36-468A-BE34-B84CA86E973DQ28326720-C549498D-FA5A-476B-8D02-F042584CA84FQ28326866-F3B823B9-C39D-48D2-8967-B7934641F05DQ28327854-5ED71408-9D2F-4AC2-8341-CA96E18087CAQ28328852-BCAE0795-F761-48B7-9F08-360F77587FF3Q28331494-A383DF67-0237-449E-BC60-BABE3EC00DE0Q28333679-A63F82D5-F8EC-4F9C-B80D-0990D5FD2DFBQ28333682-D8B98204-52EE-4634-9FDD-5BE5711C2CF5
P2860
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@ast
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@en
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@nl
type
label
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@ast
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@en
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@nl
prefLabel
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@ast
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@en
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@nl
P2093
P3181
P356
P1433
P1476
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
@en
P2093
P304
P3181
P356
10.1126/SCIENCE.2467383
P407
P577
1989-03-31T00:00:00Z